DrugComboRanker: drug combination discovery based on target network analysis

Area of Science:

• Computational biology
• Bioinformatics
• Drug discovery

Background:

• Cancer is a complex disease driven by multiple signaling pathways, leading to drug resistance.
• Drug combinations are a promising strategy to improve efficacy and overcome resistance.
• Existing computational methods are insufficient for identifying optimal drug combinations.

Purpose of the Study:

• To develop a systematic computational tool, DRUGCOMBORANKER, for prioritizing synergistic drug combinations.
• To uncover the mechanisms of action for predicted drug combinations.
• To provide a feasible approach for identifying effective drug combinations from numerous possibilities.

Main Methods:

• Constructed a drug functional network using genomic profiles and partitioned it into communities with Bayesian non-negative matrix factorization.
• Identified drug targets by applying a recommendation system on drug communities.
• Built disease-specific signaling networks and identified drug combinations targeting complementary signaling modules.

Main Results:

• DRUGCOMBORANKER successfully prioritized synergistic drug combinations for lung adenocarcinoma and breast cancer.
• The tool mapped drug targets onto disease signaling networks, elucidating mechanisms of action.
• Case studies validated the effectiveness of the identified drug combinations.

Conclusions:

• DRUGCOMBORANKER offers a novel computational approach to discover effective drug combinations for cancer therapy.
• The tool aids in understanding the mechanisms underlying drug synergy.
• This approach facilitates the development of combination therapies to combat cancer and drug resistance.